Previous close | 0.9000 |
Open | 0.9000 |
Bid | 0.0000 |
Ask | 1.2500 |
Strike | 5.00 |
Expiry date | 2024-11-15 |
Day's range | 0.9000 - 0.9000 |
Contract range | N/A |
Volume | |
Open interest | 7 |
Senior R&D leader brings extensive expertise in immunology, clinical development and translational scienceSOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today announced that translational immunology expert George Vratsanos, M.D., FACR, is joining its board of directors. Dr. Vratsanos currently serves as Chief Medical Officer and Head of R&D for Jnana Th
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Insights into Nkarta's Financial Health and Strategic Developments in Cell Therapy